April 1, 2021 -- Sanofi announced an investment of approximately $737 million U.S. in a new vaccine manufacturing facility at its existing site in Toronto, Canada, to provide additional antigen and filling capacity for Sanofi's influenza vaccine.
The investment is intended to strengthen domestic pandemic preparedness and increase global supply of Sanofi's Fluzone high-dose quadrivalent influenza vaccine, which has been recommended for use over standard-dose influenza vaccines in individual adults 65 years and older by the National Advisory Committee on Immunization in Canada.
The Sanofi Pasteur site currently manufactures millions of doses of vaccines annually against pertussis, polio, diphtheria, and tetanus, among others, for more than 60 countries worldwide. Vaccines produced at the new facility on the same site will supply influenza vaccines to Canada, the U.S., and Europe.
Following design, construction, testing, and qualification of the facility and equipment, the new facility will be operational by 2026. The investment will create 300 high quality jobs, according to the company.